Pages that link to "Q33186211"
Jump to navigation
Jump to search
The following pages link to Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study (Q33186211):
Displaying 50 items.
- Aripiprazole versus placebo for schizophrenia (Q24234961) (← links)
- Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems (Q24235450) (← links)
- Antipsychotic medication for early episode schizophrenia (Q24236683) (← links)
- Risperidone versus placebo for schizophrenia (Q24241041) (← links)
- Aripiprazole versus typical antipsychotic drugs for schizophrenia (Q24241974) (← links)
- Aripiprazole versus typicals for schizophrenia (Q24242810) (← links)
- Aripiprazole for schizophrenia (Q24246298) (← links)
- Aripiprazole for schizophrenia (Q24247235) (← links)
- Management of antipsychotic-related weight gain (Q24610124) (← links)
- Current options in the management of olanzapine-associated weight gain (Q31138909) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (Q33223628) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia (Q33235110) (← links)
- Commentary on strategies for switching antipsychotics (Q33347838) (← links)
- The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. (Q33619940) (← links)
- Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole (Q33755676) (← links)
- Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study (Q33819964) (← links)
- Aripiprazole in autism spectrum disorders and fragile X syndrome (Q34025492) (← links)
- Risk of osteoporosis and fracture incidence in patients on antipsychotic medication (Q34026011) (← links)
- The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study (Q34110039) (← links)
- Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia (Q34143822) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (Q34315836) (← links)
- Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder (Q34333899) (← links)
- Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. (Q34375654) (← links)
- Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia (Q34486175) (← links)
- Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability (Q34548876) (← links)
- Sexual dysfunction in schizophrenia: focus on recent evidence (Q34761446) (← links)
- Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). (Q34966395) (← links)
- Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. (Q35031175) (← links)
- Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia (Q35100117) (← links)
- Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia (Q35186503) (← links)
- Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management (Q35669815) (← links)
- Dopamine partial agonists: a new class of antipsychotic (Q35688765) (← links)
- Novel antipsychotics in schizophrenia (Q35753453) (← links)
- New trends in the treatment of anxiety disorders. (Q35859824) (← links)
- Aripiprazole: the evidence of its therapeutic impact in schizophrenia (Q35876413) (← links)
- Successful use of add - on topiramate for antipsychotic - induced weight gain (Q35993196) (← links)
- Switching between second-generation antipsychotics: why and how? (Q36009886) (← links)
- The art of prescribing. Principles of switching novel antipsychotic medications (Q36094872) (← links)
- The place of partial agonism in psychiatry: recent developments (Q36176852) (← links)
- A review of pharmacologic strategies for switching to atypical antipsychotics (Q36199687) (← links)
- Switching antipsychotics: an updated review with a focus on quetiapine (Q36276541) (← links)
- The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders (Q36321595) (← links)
- The metabolic effects of antipsychotic medications (Q36577856) (← links)
- Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy (Q36687342) (← links)
- Antipsychotic-induced sexual dysfunction and its management (Q36758151) (← links)
- Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus (Q36817257) (← links)
- Cardiovascular effects of antipsychotics (Q36870063) (← links)
- Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand (Q36872731) (← links)
- Metabolic side effects of antipsychotic medication (Q36879594) (← links)
- Adding or switching antipsychotic medications in treatment-refractory schizophrenia (Q36905070) (← links)